Alvio Labs

Q1 2025 Financial Summary

January 1 – March 31, 2025

Report Date: March 22, 2026

Currency: EUR

Executive Summary

Net Profit / Loss
€10,966.85
Total Expenses
€10,966.85
Cash Position
€532.14

Profit & Loss Statement

Period: January 1, 2025 to March 31, 2025

Account Amount (EUR)
Revenue
Sales Revenue 0.00
Total Revenue 0.00
Cost of Sales
Cost of Goods Sold 10,350.00
Gross Profit (10,350.00)
Operating Expenses
Bank Fees 10.00
Consulting & Accounting 405.90
Office: Software Expenses 2.68
Research & Development 198.27
Total Operating Expenses 616.85
Net Profit / (Loss) (10,966.85)

Note: No revenue recorded in Q1 2025. Expenses primarily consist of cost of goods sold (€10,350.00) and operating expenses (€616.85).

Balance Sheet Summary

As at March 31, 2025

Assets EUR
Current Assets
Revolut EUR Main 532.14
Total Assets 532.14
Liabilities & Equity EUR
Current Liabilities
Accounts Payable 405.90
Director's Current Account 13,993.09
Director's Loan Account 550.00
Total Liabilities 14,948.99
Net Assets (14,416.85)

Cash Position

Bank Account Balance (EUR)
Revolut EUR Main 532.14
Total Cash 532.14

Cash position as of March 31, 2025.

Accounts Receivable Aging

As at March 31, 2025

Aging Category Amount (EUR) % of Total
Current (0-30 days) 0.00 0%
31-60 days 0.00 0%
61-90 days 0.00 0%
Over 90 days 0.00 0%
Total Accounts Receivable 0.00 100%

No outstanding accounts receivable as of March 31, 2025. All invoices issued in Q1 2025 have been paid.